Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer | MicrobiomeTrials
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2021-10-20Est. Completion: 2025-02-15
Enrollment target: 29 participants
Locations
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
Yale University, New Haven, Connecticut, United States
Smilow Cancer Hospital Care Center-Trumbull, Trumbull, Connecticut, United States
Mayo Clinic in Florida, Jacksonville, Florida, United States
University of Kansas Clinical Research Center, Fairway, Kansas, United States
University of Kansas Cancer Center, Kansas City, Kansas, United States
University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States
University of Kansas Hospital-Indian Creek Campus, Overland Park, Kansas, United States
University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters, Missouri, United States
Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States
University of Kansas Cancer Center - North, Kansas City, Missouri, United States
Other microbiome trials you might be interested in